AASLD 2018: AASLD Presidential Poster of Distinction¹
Abstract: #584 Early Treatment with Direct-Acting Antivirals (DAAs) Saves Medical Costs in Non-Cirrhotic Patients with Chronic Hepatitis C (CHC) Virus Infection in the United States (US)- Patrice Cacoub, et. al.
The study evaluated whether DAA therapy was cost-effective in people infected with chronic hepatitis C without cirrhosis. Prior interferon and/or ribavirin-treated patients were excluded from this retrospective study. Two patient groups were identified and evenly matched by patient characteristics—one group received DAA treatment, one group did not (control group). The treated patients received DAA treatment between 2013 and 2015. Both groups were followed for a maximum of 3 years, and their medical costs were estimated. The medical costs of the two groups were compared including expenses from HCV extrahepatic manifestations (EH). The most common EH’s included fatigue (13%), type 2 diabetes (11%), and heart disease (9%). There were 3,069 patients evaluated and 852 (28%) patients treated with DAAs.
The cost savings in the DAA-treated group was significantly lower on average ($6,379 per patient, per year). The savings were mainly from a reduction in costs attributed to the care and treatment of extrahepatic manifestations.
Conclusion: Starting DAA treatment within the first three years of diagnosis of HCV is associated with significant cost savings.
Editorial Comments: This is a well-conducted study that should prompt earlier treatment of people newly diagnosed with hepatitis C. I would hope that insurance companies would consider this when evaluating approval of treatment.
¹Recipient Posters of Distinction are considered to be particularly noteworthy and represent the top 10% of all accepted poster presentationsShare This Page